In the absence of specific antibody, opsonization of Streptococcus pneumoniae may be mediated by the alternative complement pathway (AP) or by C-reactive protein (CRP) via Cl binding. To determine the role of these mechanisms in pneumococcal (PNC) disease, we studied 19 patients with differing severities of PNC infection. C4 and CRP levels and zymosan-induced consumption of 50% hemolytic complement (CH50) were measured in specimens obtained acutely and then weekly. In patients with complicated illness, the modified mean CH50 in acute sera was 178 + 57 U/ml, significantly lower than the mean CH50 of 331 + 80 U/ml in patients with uncomplicated illness (P < 0.05). The values of the two groups on a given day approximated each other on days 7, 14, and 23. Consumption of complement by zymosan was also lower in acute sera of patients with complicated illness, with a mean value of 19 ± 18 U/ml compared with 58 ± 30 U/mI in those with uncomplicated illness (P < 0.05). This difference was also seen on day 7 (P < 0.05). Disease involving lower-numbered PNC serotypes (less than 10) correlated with reduced availability of AP factors in acute sera, independent of illness severity. Mean CRP levels were inversely related to zymosan-induced complement activation in patients with complicated illness. These data suggest that in vivo depletion of AP factors is significantly greater in patients with complicated illness and is associated with high CRP levels. CRP may enhance AP activation via C3 convertase generation and function with it as a preantibody host defense mechanism.
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Recovery from bacterial infections depends in large part on the ingestion and killing of invading microorganisms by the phagocytes of the host. The encapsulated pneumococcus resists phagocytosis unless serum opsonins are available. In the absence of specific antibody, the alternative complement pathway (AP) can be activated via the cell wall teichoic acid (TA) (12, 31) . C3b thus generated fixes to TA containing cell wall polymers (26, 30, 31) , allowing granulocytes to adhere and phagocytosis to ensue. This form of opsonization proceeds without capsular material or C4 but may be facilitated by cell wall binding of nonimmunospecific immunoglobulin G (22, 28, 29) as well as by specific antibody (18) . The latter generates C3 convertase via classical pathway activation, amplifying the AP C3b feedback cycle. In addition, there is in vitro evidence for variation among pneumococcal (PNC) serotypes in their ability to activate the AP (7, 9, 22) .
Streptococcus pneumoniae may be opsonized via interaction with C-reactive protein (CRP). CRP has specific binding affinity for phosphocholine moieties (4, 14, 24) ; in the presence of calcium ions, binding of CRP to PNC cell wall constituents activates the classical complement pathway.
These constituents are probably the choline-TA-containing polymers. Mold and Gewurz showed in vitro that CRP inhibits PNC-induced AP activation in a dose-dependent fashion (16) .
This study was done to determine the relationship between severity of PNC infection, complement activation, and CRP levels. We measured the functional activity of the patients with PNC disease. Concomitant C4 and CRP levels were also measured. We expected that in vivo consumption of AP factors would reduce the factors available for in vitro Z activation; that is, the difference between CH50 content of normal saline (NS)-versus Z-treated sera would be smaller than that found in a healthy subject with undiminished initial AP content. Our observations suggest that in vivo depletion of AP factors is significantly greater in severely ill patients and is associated with high CRP levels. Table 2) .
The functional activity of the AP in patients with complicated and uncomplicated disease was compared (Fig. 1) . Acutely, depression of functional activity of the AP was seen only in the complicated subgroup, whether expressed as the mean of CH50-NS, CH50-Z, or CH50-difference (P < 0.05).
The depression of CH50-difference in patients with complicated disease compared to those with uncomplicated disease remained significant until week 2. Thus, increased severity of illness was associated with reduced availability of AP factors for in vitro activation. Because of the few patients (three) with splenectomy, we were unable to demonstrate an independent effect of this factor on AP function.
CH50 titers in patients with disease involving serotypes numerically lower or higher than 10 were compared (Fig. 2) .
The lower-than-10 patients showed significant depression of the mean CH50-difference acutely when compared to the higher-than-10 subgroup (15.3 ± 12.7 versus 46.5 ± 18.4 U/ml). This contrasted with our results when patients were grouped as good versus poor activators of the AP (see above). There were no significant differences between these subgroups, although the good activators achieved greater mean CH50-difference titers (Fig. 3) .
Studies of the functional activity of the AP for patients with bacteremia versus abacteremia failed to yield significant differences between subgroups.
CRP. Patients with complicated and uncomplicated disease had elevated mean CRP levels acutely which gradually (Fig. 4) . The difference between subgroups was not significant. Sera from patients with complicated disease had an inverse relationship between mean CRP levels and availability of AP factors for in vitro Z activation. This was not seen in the sera from the subgroup with uncomplicated disease.
Complement levels. C4 levels occasionally showed elevation or depression beyond the normal range in a given patient; however, mean C4 levels for all subgroups were normal, and no statistically significant differences were observed.
DISCUSSION
The relationships between severity of PNC infection, AP activation, and CRP levels have not been well studied. Because in vitro models may not reflect in vivo activation, we undertook a prospective study in patients with PNC infection. We chose the Z consumption assay, rather than immunochemical or immunoelectrophoretic analyses, as more accurately reflecting the in vivo activity. Although the other assays may be more sensitive in detecting small changes in component levels, our assay normalizes the large changes in baseline complement component levels due to the acute-phase response. By running each serum specimen in duplicate (with and without Z activation), each specimen serves as its own control. We found that the functional activity of the AP, as measured by Z consumption, was significantly depressed in acute sera of patients with PNC disease when compared to normal sera. This is consistent with the work of Coonrod and Rylko-Bauer which compared a population of patients with PNC pneumonia to a population of healthy controls (6) . To determine whether the population of patients with PNC disease was homogeneous with respect to AP activation, we analyzed different patient subsets. Our studies indicated that patients with more severe or complicated illness had acute sera with reduced availability of AP factors for in vitro Z activation, compared to that from uncomplicated patients. This agrees with the data of others showing greater AP depression in patients with severe bacteremic infections (6) .
Reduced availability of AP factors may reflect greater in vivo activation and consumption of the AP in the patient group with complicated disease. The resulting complement depletion may impair opsonic activity, thus compromising host defense. There is a dramatic defect in clearance of pneumococci in complement-depleted animals (2, 10). In addition, AP activation can generate activated complement components (11, 13, 21) which may produce tissue injury and lead to more severe illness. The extent of in vivo activation of complement may depend on the concentration of available antigen. In an in vitro model, >105 pneumococci per ml are required to induce measurable amounts of complement consumption (7) . Such concentrations may be achieved in acutely infected lung or meninges and may contribute to more efficient AP activation. caused by different serotypes of pneumococci, we chose subgroups with serotypes numerically higher or lower than 10. We found that sera from patients with lower serotype infections had reduced availability of AP factors for in vitro Z activation when compared to the higher-than-10 group. This was independent of illness severity. PNC serotypes differ in their in vitro ability to activate the AP and to fix C3b and initiate opsonization (7, 9, 22) . We stratified patients by serotype into good or poor AP activators according to these studies. In contrast to what one would predict, the subgroup of patients with good activator serotypes had greater availability of AP factors for Z activation. The basis for the different abilities of PNC serotypes to activate the AP is unknown. One contributing factor may be the varying mechanical barrier imposed by the particular configuration of capsular material. The cell wall binding sites for C3b, predominantly choline-TA (12, 26, 31) , lie deep to the capsular polysaccharides that are ineffective in activating AP (27) . The varying ability of PNC serotypes to activeate AP may be a reflection of different exposure of the binding sites to C3b.
The third patient classification factor we examined was bacteremia versus abacteremia. Our studies demonstrated that bacteremia was not independently associated with availability of AP factors for Z activation. This indicated that the bacteremic patients were a subgroup different from the patients with complicated disease. Coonrod and RylkoBauer found greater depression of the AP in bacteremic patients (6) . However, those patients also had more severe and complicated infections. Bacteremia may not be the most critical element in determining AP activation. There are seldom more than several hundred pneumococci per ml in the circulating blood of patients with PNC pneumonia (23) . With respect to AP activation, the quantity of bacteria in the blood may be inconsequential compared to the quantity of antigen released into the bloodstream or present in lung or meninges. Bukantz et al. showed that mortality due to PNC disease correlates more highly with circulating capsular polysaccharide than with bacteremia (3). C-substance (TA), a potent AP activator, as well as capsular polysaccharide may diffuse into blood independent of the presence of viable organisms in the circulation (5, 15) .
Significant morbidity and mortality from PNC disease continue to occur despite rapid killing of PNC by antibiotics (17) . An inflammatory process ensues, with systemic dissemination of inflammatory substances in severe PNC infection (11, 13, 21) . This process may involve CRP. In the preantibody phase of PNC infection, binding of the antibody-like CRP to cell wall choline-TA activates the classical complement pathway (4, 14, 24) . Specific antibody induces classical pathway activation (18) , resulting in generation of C3b and amplifying the AP autocatalytic sequence (25) . CRP may similarly result in augmented AP activity. We observed a marked increase in concentration of CRP in acute sera of patients with PNC disease. In patients with complicated illness, there was an inverse relationship between CRP levels and availability of AP factors for Z activation. This may simply be independent consequences of greater severity of disease or numbers of microorganisms. We found normal C4 levels in patients, confirming the findings of others of normal early classical complement pathway components in PNC infection (6, 19, 20) . Prellner noted that despite normal Cl levels, there are elevated levels of activated Cl complexes in patients with PNC pneumonia or meningitis, and she concluded that consumption of early components may be masked by an acute-phase response (19) . Similarly, consumption of CRP may be masked by an acute-phase response. Measureable CRP levels may also be influenced by competition with AP factors for common cell wall (TA) binding sites. Mold and Gewurz examined the in vitro interaction of CRP with PNC-induced AP activation (16) . Using C2 deficient sera, they found a dose-dependent inhibition of C3 conversion by PNC in the presence of CRP. However, in vivo, AP factors may have a temporal advantage in the competition for TA binding, permitting AP activation while blocking CRP binding. This may further augment the levels of CRP seen in the presence of AP activation. Such dynamics may reconcile the difference between activation of the AP in the in vitro model (16) and that proposed by us to occur in vivo.
